^
    Back
    Association details:
    Biomarker:IDH2 mutation + Chr del(1p) + Chr del(19q)
    Cancer:Oligodendroglioma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: OLIGODENDROGLIOMA (IDH-MUTANT, 1p19q CODELETED)….Recurrent Disease, WHO grade 3, KPS ≥60….Other Recommended Regimens...Systemic therapy+ bevacizumab...Carmustine or lomustine + bevacizumab...TMZ + bevacizumab
    Secondary therapy:
    lomustine; temozolomide; carmustine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: OLIGODENDROGLIOMA (IDH-MUTANT, 1p19q CODELETED)….Recurrent Disease, WHO grade 3, KPS ≥60….Preferred Regimens...bevacizumab